Legal Cases Involve Elmiron Causing Eye Damage and Retinal Injury Such as Atypical or Pigmentary Maculopathy

 

(Posted by Tom Lamb at Drug Injury Watch)

 

On December 15, 2020, the Judicial Panel on Multidistrict Litigation (JPMDL) granted a plaintiffs’ motion to centralize all currently filed federal court lawsuits involving the bladder drug Elmiron and assigned that multidistrict litigation (MDL) to the U.S. District Court for the District of New Jersey. This Elmiron MDL  was assigned to U.S. District Judge Brian Martinotti, who oversee these Elmiron lawsuits which allege that Elmiron — a pill used to treat chronic bladder infection called interstitial cystitis — can cause Elmiron-related eye problems that can lead to vision loss or blindness.

In this September 2020 article, “Elmiron-Related Eye Problems Are Causing Patients to File Elmiron Lawsuits Against Pharmaceutical Companies, we explained the factual basis for the Elmiron lawsuits which will be included in this new Elmiron MDL:

Elmiron (pentosan polysulfate sodium / “PPS”) was approved by the FDA in 1996 for the treatment of interstitial cystitis (“IC”), also known as “bladder pain syndrome” or “painful bladder syndrome”. In recent years, however, there have been reports of patients who used Elmiron developing vision loss due to Elmiron-related maculopathy. But there were not any warnings about these Elmiron eye problems in the Elmiron Prescribing Information document, or drug label, until June 2020, when the FDA mandated an Elmiron label change. This situation has resulted in Elmiron lawsuits filed by patients who have vision loss due to Elmiron.

From the Transfer Order issued for In Re: Elmiron [Pentosan Polysulfate Sodium] Products Liability Litigation, MDL Docket No. 2973, we get the following legal information:

Plaintiffs in the District of New Jersey Dobbins action move under 28 U.S.C. § 1407 to centralize this litigation involving retinal injuries associated with the use of Elmiron (pentosan polysulfate sodium)….

No responding party opposes centralization….

After considering the argument of counsel, we find that centralization of these actions in the District of New Jersey will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. The actions involve common factual issues concerning the propensity of Elmiron to cause retinal injuries, notably atypical or pigmentary maculopathy. Several defendants have marketed Elmiron since its approval in 1996. This litigation likely will implicate complex scientific and regulatory issues. Centralization will eliminate duplicative discovery; avoid inconsistent pretrial rulings; and conserve the resources of the parties, their
counsel and the judiciary. [Footnote omitted.]

We are currently investigating possible Elmiron lawsuits for patients diagnosed with Elmiron-related eye problems such as:

  • wither pigmentation maculopathy
  • pigmentation macular degeneration
  • pigmentation maculitis
  • retinal maculopathy
  • dry macular degeneration

We point out that a person does not need to have been using Elmiron at the time when their eye damage or retinal injury was diagnosed by a doctor in order to be in a position to file an Elmiron lawsuit.

If we can be of assistance to you or someone else regarding a possible Elmiron lawsuit, you can send an email to Tom Lamb or you can call us on our toll-free number: 800-426-9535.


DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects
 (All website content by attorney Tom Lamb)

Drug Injury Case Evaluation – Free. Confidential. No Obligation.  (Case review is done by attorney Tom Lamb)